[Acellular pertussis vaccine (Pa)].
Vaccination by whole-cell pertussis vaccine (Pw) since forties years was followed by decreasing of morbidity and especially mortality caused by pertussis. High reactogenicity of this vaccine (Pw) was the reason trials undertaken to search new type of less reactogenic vaccine. Acellular pertussis vaccine (Pa) was found as effective, safe, small reactogenic. It may be especially used as booster doses for older children and even for adults people. Actual pertussis infection among adults are suspected as the source infection for children. Just now in some countries acellular vaccine start to be used for ground vaccination of children. Increasing of morbidity of pertussis was noted in some provinces in Poland in last time. Acellular pertussis vaccine may be introduced as booster dose for 6-7 years old children, if epidemiological situation of pertussis among school-age children would be not satisfied in future.
D000328:Adult; D002648:Child; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D010567:Pertussis Vaccine / Q000008:administration & dosage*; D011044:Poland / Q000453:epidemiology; D015996:Survival Rate; D014917:Whooping Cough / Q000401:mortality / Q000517:prevention & control* / Q000635:transmission
D010567:Pertussis Vaccine
Acelularna szczepionka przeciw krztuścowi (Pa).